International severe asthma registry (ISAR): protocol for a global registry.

Disease registry Protocol Real-world Severe asthma

Journal

BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545

Informations de publication

Date de publication:
14 08 2020
Historique:
received: 11 12 2019
accepted: 26 06 2020
entrez: 22 8 2020
pubmed: 21 8 2020
medline: 25 6 2021
Statut: epublish

Résumé

Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour. ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (≥18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders. ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally.

Sections du résumé

BACKGROUND
Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour.
METHODS
ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (≥18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders.
CONCLUSIONS
ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally.

Identifiants

pubmed: 32819285
doi: 10.1186/s12874-020-01065-0
pii: 10.1186/s12874-020-01065-0
pmc: PMC7439682
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

212

Références

J Manag Care Spec Pharm. 2016 Jul;22(7):848-61
pubmed: 27348285
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
J Allergy Clin Immunol Pract. 2019 Feb;7(2):578-588.e2
pubmed: 30179741
Respir Med. 2014 Dec;108(12):1723-32
pubmed: 25456708
J Asthma. 2012 May;49(4):416-22
pubmed: 22443408
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Respir Med. 2018 Dec;145:41-47
pubmed: 30509715
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468
pubmed: 30368004
J Allergy Clin Immunol. 2010 Nov;126(5):926-38
pubmed: 20926125
Ann N Y Acad Sci. 2008;1136:161-71
pubmed: 17954679
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):120-9.e3
pubmed: 26439182
Allergy. 2013 Jul;68(7):836-43
pubmed: 23735183
Can Respir J. 2010 Mar-Apr;17(2):74-80
pubmed: 20422063
J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5
pubmed: 23040887
Health Qual Life Outcomes. 2010 Sep 08;8:96
pubmed: 20825674
Hum Mutat. 2013 Nov;34(11):1449-57
pubmed: 23913485
Pneumologie. 2012 Jun;66(6):341-4
pubmed: 22477565
Acta Neurol Scand Suppl. 2012;(195):24-30
pubmed: 23278653
ERJ Open Res. 2018 Mar 06;4(1):
pubmed: 29531957
J Allergy Clin Immunol. 2015 Apr;135(4):896-902
pubmed: 25441637
Ann Rheum Dis. 2016 Oct;75(10):1797-805
pubmed: 26857699
J Allergy Clin Immunol. 2018 May;141(5):1590-1597.e9
pubmed: 28797732
Am J Respir Crit Care Med. 2018 Jan 1;197(1):22-37
pubmed: 28910134
Thorax. 2010 Sep;65(9):787-94
pubmed: 20805172
N Engl J Med. 2009 Mar 5;360(10):973-84
pubmed: 19264686
J Allergy Clin Immunol. 2017 Jun;139(6):1797-1807
pubmed: 27773852
Lancet. 2018 Jan 27;391(10118):350-400
pubmed: 28911920
J Allergy Clin Immunol. 2014 Jun;133(6):1557-63.e5
pubmed: 24332216
Chest. 2020 Apr;157(4):790-804
pubmed: 31785254

Auteurs

J Mark FitzGerald (JM)

The Institute for Heart Lung Health, Vancouver, Canada.

Trung N Tran (TN)

AstraZeneca, Gaithersburg, USA.

Marianna Alacqua (M)

AstraZeneca, Gaithersburg, USA.

Alan Altraja (A)

Department of Pulmonary Medicine, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, Estonia.

Vibeke Backer (V)

Center of Physical Activity Research, Rigshospitalet and Copenhagen University, Copenhagen, Denmark.

Leif Bjermer (L)

Department of Respiratory Medicine & Allergology, Skåne University Hospital, Lund, Sweden.

Unnur Bjornsdottir (U)

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Arnaud Bourdin (A)

Department of Respiratory Diseases, Montpellier University Hospitals, Hopital Arnaud de Villeneuve and PhyMed Exp (INSERM U 1046, CNRS UMR9214), Universite de Montpellier, Montpellier, France.

Guy Brusselle (G)

Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Departments of Epidemiology and Respiratory Medicine, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.

Lakmini Bulathsinhala (L)

Optimum Patient Care, Cambridge, UK.

John Busby (J)

Centre for Public Health, Queen's University Belfast, Belfast, UK.

Giorgio W Canonica (GW)

Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research Hospital, Milan, Italy.
SANI-Severe Asthma Network Italy, Milan, Italy.

Victoria Carter (V)

Optimum Patient Care, Cambridge, UK.

Isha Chaudhry (I)

Optimum Patient Care, Cambridge, UK.

You Sook Cho (YS)

Division of Allergy, Department of Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea.

George Christoff (G)

Faculty of Public Health, Medical University - Sofia, Sofia, Bulgaria.

Borja G Cosio (BG)

Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain.

Richard W Costello (RW)

Clinical Research Centre, Smurfit Building Beaumont Hospital and Department of Respiratory Medicine, RCSI, Dublin, Ireland.

Neva Eleangovan (N)

Optimum Patient Care, Cambridge, UK.

Peter G Gibson (PG)

Australasian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, Australia.
Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, New Lambton Heights, Australia.

Liam G Heaney (LG)

Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.

Enrico Heffler (E)

Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research Hospital, Milan, Italy.
SANI-Severe Asthma Network Italy, Milan, Italy.

Mark Hew (M)

Alfred Health & Monash University, Melbourne, Australia.

Naeimeh Hosseini (N)

Optimum Patient Care, Cambridge, UK.

Takashi Iwanaga (T)

Department of Respiratory Medicine & Allergology, Faculty of Medicine, Kindai University Hospital, Ōsakasayama, Japan.

David J Jackson (DJ)

Guy's & St Thomas' NHS Trust and King's College London, London, UK.

Rupert Jones (R)

Faculty of Medicine & Dentistry, University of Plymouth, Plymouth, UK.

Mariko S Koh (MS)

Department of Respiratory & Critical Care Medicine, Singapore General Hospital and Duke-National University Singapore Medical School, Singapore, Singapore.

Thao Le (T)

Optimum Patient Care, Cambridge, UK.

Lauri Lehtimäki (L)

Allergy Centre, Tampere University Hospital and Tampere University, Tampere, Finland.

Dora Ludviksdottir (D)

Department of Respiratory Medicine, Faculty of Medicine, Landspitali University Hospital and University of Iceland, Reykjavik, Iceland.

Anke H Maitland-van der Zee (AH)

University of Amsterdam, Amsterdam, The Netherlands.

Andrew Menzies-Gow (A)

Royal Brompton & Harefield NHS Foundation Trust, London, UK.

Ruth B Murray (RB)

Optimum Patient Care, Cambridge, UK.

Nikolaos G Papadopoulos (NG)

University of Athens, Athens, Greece.
University of Manchester, Manchester, UK.

Luis Perez-de-Llano (L)

Pneumology Service, Hospital Universitario Lucus Augusti, Lugo, Spain.

Matthew Peters (M)

University of Sydney Medical School, Sydney, Australia.

Paul E Pfeffer (PE)

UK Severe Asthma Network, Barts Health NHS Trust and Queen Mary University of London, London, UK.

Todor A Popov (TA)

University Hospital "Sv. Ivan Rilski", Sofia, Bulgaria.

Celeste M Porsbjerg (CM)

Bispebjerg Hospital, Copenhagen University, Copenhagen, Denmark.

Chris A Price (CA)

Optimum Patient Care, Cambridge, UK.

Chin K Rhee (CK)

The Catholic University of Korea, Seoul, South Korea.

Mohsen Sadatsafavi (M)

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.

Yuji Tohda (Y)

Department of Respiratory Medicine & Allergology, Faculty of Medicine, Kindai University Hospital, Ōsakasayama, Japan.

Eileen Wang (E)

Division of Allergy & Clinical Immunology, Department of Medicine, National Jewish Health and Division of Allergy & Clinical Immunology, Department of Internal Medicine, University of Colorado Hospital, Denver and Aurora, CO, USA.

Michael E Wechsler (ME)

Division of Pulmonary, Critical Care and Sleep Medicine, Asthma Program, National Jewish Health, Denver, USA.

James Zangrilli (J)

AstraZeneca, Gaithersburg, USA.

David B Price (DB)

Optimum Patient Care, Cambridge, UK. dprice@opri.sg.
Observational and Pragmatic Research Institute, Singapore, Singapore. dprice@opri.sg.
Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. dprice@opri.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH